

- 1 -

## SEQUENCE LISTING

&lt;110&gt; Bayer AG, BHC

<120> Diagnostics and Therapeutics for Diseases Associated with Kallikrein  
9 (KLK9)

&lt;130&gt; Le A 36 871

&lt;160&gt; 5

&lt;170&gt; PatentIn version 3.1

&lt;210&gt; 1

&lt;211&gt; 753

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

```

atgaagctgg gactcctctg tgctctgctc tctctgctgg cagggcatgg ctgggcagac      60
acccgtgccg tcggggccga ggaatgtcgc cccaactccc agccttggca ggccggcctc      120
ttccacctta ctggctctct ctgtggggcg accctcatca gtgaccgctg gctgtctaca      180
gctgccactt gccgaagcc gtatctgttg gtcgccttg gagagacca cctctggaaa      240
tgggagggtc cggagcagct gttccgggtt acggacttct tccccaccc tggcttcaac      300
aaggacctca gcgcaatga ccacaatgat gacatcatgc tgatccgcct gccaggcag      360
gcacgtctga gtcctgtgtg gcagccctc aacctcagcc agacctgtgt ctcccaggc      420
atgcagtgtc tcctctcagg ctggggggcc gtgtccagcc ccaaggcgct gtttccagtc      480
acactgcagt gtgccaacat cagcatcctg gagaacaaac tctgtcactg ggcataccct      540
ggacacatct cggacagcat gctctgtgcg ggcctgtggg aggggggccc aggttcctgc      600
cagggtgact ctggggggcc cctggtttgc aatggaacct tggcaggcgt ggtgtctggg      660
ggtgtctgag cctgtctcag accccggcgc ccgcagctct acaccagcgt atgccactac      720
cttgactgga tccaagaaat catggagaac tga                                     753

```

&lt;210&gt; 2

&lt;211&gt; 250

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

Met Lys Leu Gly Leu Leu Cys Ala Leu Leu Ser Leu Leu Ala Gly His
1           5           10           15
Gly Trp Ala Asp Thr Arg Ala Ile Gly Ala Glu Glu Cys Arg Pro Asn
35          20          25          30
Ser Gln Pro Trp Gln Ala Gly Leu Phe His Leu Thr Arg Leu Phe Cys
35          40          45
Gly Ala Thr Leu Ile Ser Asp Arg Trp Leu Leu Thr Ala Ala His Cys
50          55          60
Arg Lys Pro Tyr Leu Trp Val Arg Leu Gly Glu His His Leu Trp Lys
65          70          75          80
Trp Glu Gly Pro Glu Gln Leu Phe Arg Val Thr Asp Phe Phe Pro His
85          90          95

```

- 2 -

Pro Gly Phe Asn Lys Asp Leu Ser Ala Asn Asp His Asn Asp Asp Ile  
 100 105 110  
 Met Leu Ile Arg Leu Pro Arg Gln Ala Arg Leu Ser Pro Ala Val Gln  
 115 120 125  
 5 Pro Leu Asn Leu Ser Gln Thr Cys Val Ser Pro Gly Met Gln Cys Leu  
 130 135 140  
 Ile Ser Gly Trp Gly Ala Val Ser Ser Pro Lys Ala Leu Phe Pro Val  
 145 150 155 160  
 Thr Leu Gln Cys Ala Asn Ile Ser Ile Leu Glu Asn Lys Leu Cys His  
 10 165 170 175  
 Trp Ala Tyr Pro Gly His Ile Ser Asp Ser Met Leu Cys Ala Gly Leu  
 180 185 190  
 Trp Glu Gly Gly Arg Gly Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu  
 195 200 205  
 15 Val Cys Asn Gly Thr Leu Ala Gly Val Val Ser Gly Gly Ala Glu Pro  
 210 215 220  
 Cys Ser Arg Pro Arg Arg Pro Ala Val Tyr Thr Ser Val Cys His Tyr  
 225 230 235 240  
 Leu Asp Trp Ile Gln Glu Ile Met Glu Asn  
 20 245 250  
 <210> 3  
 <211> 19  
 <212> DNA  
 <213> artificial sequence  
 25 <220>  
 <223> forward primer  
 <400> 3  
 gcgctgtttc cagtcacac 19  
 <210> 4  
 30 <211> 21  
 <212> DNA  
 <213> artificial sequence  
 <220>  
 <223> reverse primer  
 35 <400> 4  
 gcccagtgac agagtttggt c 21  
 <210> 5  
 <211> 24  
 <212> DNA  
 40 <213> artificial sequence  
 <220>  
 <223> probe  
 <400> 5  
 cagtgtgccacacatcagcat cctg 24